OncoMatch/Clinical Trials/NCT04242017
Long-term Better Than Short-term ADT With Salvage RT
Is NCT04242017 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies Triptoreline for prostate cancer.
Treatment: Triptoreline — A randomized, multicenter, prospective PHASE II trial to assess the effect of short- versus long-term adjuvant ADT with high dose salvage radiotherapy on distant metastasis free survival in case of biochemical relapse (BR) after radical prostatectomy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Excluded: Stage PN1, M1A-C
All patients have to be pN0. Presence of pN1 disease at original surgical specimen [excluded]. Presence of distant metastasis at time of referral (M1a-c) [excluded].
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: radical prostatectomy
treated with RP
Must have received: extended pelvic lymph node dissection
treated with ... ePLND
Cannot have received: radiation therapy
Exception: previous RT making new RT impossible (overlapping treatment fields)
Previous RT making new RT impossible (overlapping treatment fields) [excluded].
Cannot have received: androgen deprivation therapy
Active treatment with ADT ... [excluded].
Cannot have received: PSA modulating drugs (finasteride, dutasteride, high-dose corticoids)
Active treatment with ... PSA modulating drugs (finasteride, dutasteride, high-dose corticoids…) [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify